Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Ofatumumab (Primary) ; Bendamustine; Carboplatin; Etoposide
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Nov 2018.
- 04 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Apr 2020.